Abstract
Parkinson disease (PD) and Huntington disease (HD) are neurogenerative diseases that result in a spectrum of movement disorders. In both illnesses, the primary dysfunction is localized to the basal ganglia, a network of neural loops that mediate the execution of learned motor programs. The pharmacotherapy of both illnesses targets neurotransmitter systems of the basal ganglia. In the case of PD, dopaminergic neurotransmission is augmented to improve spontaneous movements. In HD, dopamine neurotransmission is inhibited to decrease involuntary movements.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call